Imiquimod is a prescription medicine indicated for the topical treatment of clinically typical, visible, or palpable actinic keratoses (AK) of the face or balding scalp in immunocompetent adults, among other approved uses. MedsAcross supplies Imiquimod for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Imiquimod Cream, 3.75% is indicated for the topical treatment of clinically typical, visible, or palpable actinic keratoses (AK) of the face or balding scalp in immunocompetent adults. Imiquimod Cream, 3.75% is indicated for the topical treatment of external genital and perianal warts (EGW) in immunocompetent patients 12 years of age or older.
Source: US FDA prescribing information
The mechanism of action of Imiquimod Cream in the treatment of AK and EGW is unknown.
Source: US FDA prescribing information
For topical use only, Imiquimod Cream is not for oral, ophthalmic, intra-anal or intravaginal use. For topical use only, not for oral, ophthalmic, intra-anal or intravaginal use. AK: Apply a thin layer once daily at bedtime to affected area (either entire face or balding scalp) for two 2-week treatment cycles separated by a 2-week no-treatment period. Apply up to 0.5 grams at each application. EGW: Apply a thin layer once daily at bedtime until total clearance or up to 8 weeks. Apply up to 0.25 grams at each application.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Local Skin Reactions: Intense local inflammatory reactions can occur (e.g., skin weeping, erosion). Dosage interruption may be required. Severe vulvar swelling may occur and lead to urinary retention, interrupt dosing or discontinue for severe vulvar swelling. Systemic Reactions: Flu-like signs and symptoms have occurred. Consider dosage interruption for systemic reactions. Ultraviolet Light Exposure Risks: Avoid or minimize exposure to sunlight and sunlamps. Wear protective clothing.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Local Skin Reactions Systemic Reactions Most common adverse reactions (≥4%) are local skin reactions (erythema, scabbing/crusting, flaking/scaling/dryness, edema, erosion/ulceration, exudate), headache, application site pain, application site irritation, application site pruritus, fatigue, influenza-like illness, and nausea.
Source: US FDA prescribing information
Store at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F). Avoid freezing. Store Imiquimod Cream pump bottles upright.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
4 presentations of Imiquimod, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Imiquimod 5% creamTopicalGeneric name | — | US FDA | Available on request |
| Imiquimod 3.75% creamTopicalGeneric name | — | US FDA | Available on request |
| Zyclara 3.75% creamTopical | Bausch Health | US FDA | Available on request |
| Zyclara 0.25% creamTopical | Bausch Health | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Imiquimod in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 4 presentations of Imiquimod and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Imiquimod, including Zyclara.
Yes. The US FDA first approved Imiquimod on 27 February 1997, according to Drugs@FDA.
Yes. Imiquimod has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Imiquimod is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Imiquimod is classified under ATC code D06BB10 (Imiquimod).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.